• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Papillary thyroid microcarcinoma: characteristics at presentation, and evaluation of clinical and histological features associated with a worse prognosis in a Latin American cohort.甲状腺微小乳头状癌:拉丁美洲队列中的临床表现特征以及与预后较差相关的临床和组织学特征评估
Arch Endocrinol Metab. 2018 Feb;62(1):6-13. doi: 10.20945/2359-3997000000013.
2
Radioactive iodine ablation does not prevent recurrences in patients with papillary thyroid microcarcinoma.放射性碘消融术并不能预防甲状腺微小乳头状癌患者的复发。
Clin Endocrinol (Oxf). 2013 Apr;78(4):614-20. doi: 10.1111/cen.12034.
3
A comparison of the 7th and 8th editions of the AJCC staging system in terms of predicting recurrence and survival in patients with papillary thyroid carcinoma.第 7 版和第 8 版 AJCC 分期系统在预测甲状腺乳头状癌患者复发和生存方面的比较。
Oral Oncol. 2018 Dec;87:158-164. doi: 10.1016/j.oraloncology.2018.11.003. Epub 2018 Nov 9.
4
A Comparison of the Seventh and Eighth Editions of the AJCC Staging Systems to Predict Recurrence in Papillary Thyroid Microcarcinoma.AJCC 分期系统第七版与第八版预测甲状腺微小乳头状癌复发的比较。
Ann Surg Oncol. 2021 Oct;28(11):6564-6571. doi: 10.1245/s10434-021-09596-6. Epub 2021 Jan 31.
5
Does the ATA Risk Stratification Apply to Patients with Papillary Thyroid Microcarcinoma?ATA 风险分层是否适用于甲状腺微小乳头状癌患者?
World J Surg. 2020 Feb;44(2):452-460. doi: 10.1007/s00268-019-05215-4.
6
Cancer recurrence in papillary thyroid microcarcinoma: a multivariate analysis on 231 patients with a 12-year follow-up.甲状腺微小乳头状癌的癌症复发:对231例患者进行12年随访的多因素分析
Minerva Endocrinol. 2013 Sep;38(3):269-79.
7
Partial thyroidectomy for papillary thyroid microcarcinoma: Is completion total thyroidectomy indicated?甲状腺微小乳头状癌行甲状腺腺叶切除术:是否需要行甲状腺全切除术?
Int J Surg. 2017 May;41 Suppl 1:S34-S39. doi: 10.1016/j.ijsu.2017.02.012.
8
Clinicopathological, immunohistochemical factors and recurrence associated with extrathyroidal extension in papillary thyroid microcarcinoma.甲状腺微小乳头状癌甲状腺外侵犯相关的临床病理、免疫组化因素及复发情况
J Cancer Res Ther. 2014 Jan-Mar;10(1):50-5. doi: 10.4103/0973-1482.131366.
9
Risk factors contributing to the difference in prognosis for papillary versus micropapillary thyroid carcinoma.导致甲状腺乳头癌和微小乳头状癌预后差异的风险因素。
Am J Surg. 2013 Oct;206(4):586-93. doi: 10.1016/j.amjsurg.2013.02.008. Epub 2013 Jun 19.
10
ANALYSIS OF POSTOPERATIVE ULTRASONOGRAPHY SURVEILLANCE AFTER HEMITHYROIDECTOMY IN PATIENTS WITH PAPILLARY THYROID MICROCARCINOMA: A MULTICENTER STUDY.甲状腺微小乳头状癌患者半甲状腺切除术后超声监测分析:一项多中心研究
Endocr Pract. 2017 Jul;23(7):794-802. doi: 10.4158/EP161723.OR. Epub 2017 Apr 27.

引用本文的文献

1
Papillary Thyroid Microcarcinoma in Thyroid Surgical Practice: Incidental vs. Non-Incidental: A Ten-Year Comparative Study.甲状腺外科实践中的甲状腺微小乳头状癌:意外发现型与非意外发现型:一项十年对比研究
Cancers (Basel). 2025 Jun 18;17(12):2029. doi: 10.3390/cancers17122029.
2
Influence of Tumor Laterality and Focality on Clinical Implications and Tumor Advancement in Well-Differentiated Thyroid Cancer.肿瘤侧别和灶性对分化型甲状腺癌临床意义及肿瘤进展的影响
Cancers (Basel). 2024 Dec 7;16(23):4109. doi: 10.3390/cancers16234109.
3
The impact of lymph node ratio on disease recurrence in papillary thyroid microcarcinoma.淋巴结比率对甲状腺微小乳头状癌疾病复发的影响。
Ann R Coll Surg Engl. 2023 Sep;105(7):632-638. doi: 10.1308/rcsann.2022.0094.
4
Incidentally discovered papillary thyroid microcarcinoma in patients undergoing thyroid surgery for benign disease.在因良性疾病接受甲状腺手术的患者中偶然发现甲状腺乳头状微小癌。
Endocrine. 2022 Aug;77(2):325-332. doi: 10.1007/s12020-022-03089-6. Epub 2022 May 31.
5
Characteristics and Management of Papillary Thyroid Microcarcinoma in the United Arab Emirates: Experience from a Large Tertiary Hospital.阿拉伯联合酋长国甲状腺微小乳头状癌的特征与管理:来自一家大型三级医院的经验
Saudi J Med Med Sci. 2022 Jan-Apr;10(1):42-48. doi: 10.4103/sjmms.sjmms_393_21. Epub 2022 Jan 17.
6
A Radiomic Nomogram for the Ultrasound-Based Evaluation of Extrathyroidal Extension in Papillary Thyroid Carcinoma.一种基于超声评估甲状腺乳头状癌甲状腺外侵犯的影像组学列线图。
Front Oncol. 2021 Mar 4;11:625646. doi: 10.3389/fonc.2021.625646. eCollection 2021.
7
Analysis of Curative Effect and Influencing Factors of N1 Stage Papillary Thyroid Micro-Carcinoma and Papillary Thyroid Non-Micro Carcinoma After Initial Radioactive Iodine Ablation Therapy.N1期甲状腺微小乳头状癌和甲状腺非微小乳头状癌首次放射性碘消融治疗后的疗效及影响因素分析
Cancer Manag Res. 2021 Feb 12;13:1427-1434. doi: 10.2147/CMAR.S292395. eCollection 2021.
8
Evaluation of surgical risk and prognosis between thyroid nodules of size <1 and ≥1 cm.直径<1厘米和≥1厘米的甲状腺结节手术风险及预后评估。
Gland Surg. 2019 Dec;8(6):674-682. doi: 10.21037/gs.2019.11.11.
9
Computed Tomography Radiomic Nomogram for Preoperative Prediction of Extrathyroidal Extension in Papillary Thyroid Carcinoma.用于术前预测甲状腺乳头状癌甲状腺外侵犯的计算机断层扫描影像组学列线图
Front Oncol. 2019 Sep 4;9:829. doi: 10.3389/fonc.2019.00829. eCollection 2019.
10
The Janus faces of thyroid carcinoma.甲状腺癌的双面性。
Arch Endocrinol Metab. 2018 Feb;62(1):1-3. doi: 10.20945/2359-3997000000001.

本文引用的文献

1
Lack of Efficacy of Radioiodine Remnant Ablation for Papillary Thyroid Microcarcinoma: Verification Using Inverse Probability of Treatment Weighting.放射性碘残余消融治疗甲状腺微小乳头状癌无效:应用逆概率治疗加权法验证。
Ann Surg Oncol. 2017 Sep;24(9):2596-2602. doi: 10.1245/s10434-017-5910-7. Epub 2017 Jun 9.
2
Current Management of Low Risk Differentiated Thyroid Cancer and Papillary Microcarcinoma.低风险分化型甲状腺癌和甲状腺微小乳头状癌的当前管理
Clin Oncol (R Coll Radiol). 2017 May;29(5):290-297. doi: 10.1016/j.clon.2016.12.009. Epub 2017 Jan 10.
3
Cervical Lymph Node Metastases After Thyroidectomy for Papillary Thyroid Carcinoma Usually Remain Stable for Years.甲状腺乳头状癌甲状腺切除术后的颈部淋巴结转移通常多年保持稳定。
Thyroid. 2016 Dec;26(12):1706-1711. doi: 10.1089/thy.2016.0225. Epub 2016 Oct 12.
4
Papillary thyroid microcarcinoma: time to shift from surgery to active surveillance?甲状腺微小乳头状癌:是否应该从手术转为主动监测?
Lancet Diabetes Endocrinol. 2016 Nov;4(11):933-942. doi: 10.1016/S2213-8587(16)30180-2. Epub 2016 Aug 20.
5
Inter-Observer Variation in the Pathologic Identification of Minimal Extrathyroidal Extension in Papillary Thyroid Carcinoma.甲状腺乳头状癌最小甲状腺外侵犯病理识别中的观察者间差异
Thyroid. 2016 Apr;26(4):512-7. doi: 10.1089/thy.2015.0508.
6
An International Multi-Institutional Validation of Age 55 Years as a Cutoff for Risk Stratification in the AJCC/UICC Staging System for Well-Differentiated Thyroid Cancer.一项关于将55岁作为AJCC/UICC高分化甲状腺癌分期系统中风险分层临界值的国际多机构验证研究。
Thyroid. 2016 Mar;26(3):373-80. doi: 10.1089/thy.2015.0315. Epub 2016 Feb 25.
7
Microscopic Positive Tumor Margin Does Not Increase the Risk of Recurrence in Patients with T1-T2 Well-Differentiated Thyroid Cancer.显微镜下肿瘤切缘阳性不会增加T1-T2期高分化甲状腺癌患者的复发风险。
Ann Surg Oncol. 2016 May;23(5):1446-51. doi: 10.1245/s10434-015-4998-x. Epub 2015 Dec 1.
8
Partial Thyroidectomy for Papillary Thyroid Microcarcinoma: Is Completion Total Thyroidectomy Indicated?甲状腺乳头状微小癌的甲状腺部分切除术:是否需要行甲状腺全切术?
World J Surg. 2016 Mar;40(3):510-5. doi: 10.1007/s00268-015-3327-7.
9
Minimal extrathyroid extension in papillary thyroid carcinoma does not result in increased rates of either cause-specific mortality or postoperative tumor recurrence.甲状腺乳头状癌的最小甲状腺外扩展不会导致特定病因死亡率或术后肿瘤复发率增加。
Surgery. 2016 Jan;159(1):11-9. doi: 10.1016/j.surg.2015.05.046. Epub 2015 Oct 26.
10
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.2015年美国甲状腺协会成人甲状腺结节和分化型甲状腺癌管理指南:美国甲状腺协会甲状腺结节和分化型甲状腺癌指南工作组
Thyroid. 2016 Jan;26(1):1-133. doi: 10.1089/thy.2015.0020.

甲状腺微小乳头状癌:拉丁美洲队列中的临床表现特征以及与预后较差相关的临床和组织学特征评估

Papillary thyroid microcarcinoma: characteristics at presentation, and evaluation of clinical and histological features associated with a worse prognosis in a Latin American cohort.

作者信息

Domínguez José M, Nilo Flavia, Martínez María T, Massardo José M, Muñoz Sueli, Contreras Tania, Carmona Rocío, Jerez Joaquín, González Hernán, Droppelmann Nicolás, León Augusto

机构信息

Department of Endocrinology, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.

Department of Surgery, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.

出版信息

Arch Endocrinol Metab. 2018 Feb;62(1):6-13. doi: 10.20945/2359-3997000000013.

DOI:10.20945/2359-3997000000013
PMID:29694628
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10118695/
Abstract

Objective We aimed to describe the presentation of papillary microcarcinoma (PTMC) and identify the clinical and histological features associated with persistence/recurrence in a Latin American cohort. Subjects and methods Retrospective study of PTMC patients who underwent total thyroidectomy, with or without radioactive iodine (RAI), and who were followed for at least 2 years. Risk of recurrence was estimated with ATA 2009 and 2015 classifications, and risk of mortality with 7th and 8th AJCC/TNM systems. Clinical data obtained during follow-up were used to detect structural and biochemical persistence/recurrence. Results We included 209 patients, predominantly female (90%), 44.5 ± 12.6 years old, 183 (88%) received RAI (90.4 ± 44.2 mCi), followed-up for a median of 4.4 years (range 2.0-7.8). The 7th and 8th AJCC/TNM system classified 89% and 95.2% of the patients as stage I, respectively. ATA 2009 and ATA 2015 classified 70.8% and 78.5% of the patients as low risk, respectively. Fifteen (7%) patients had persistence/recurrence during follow-up. In multivariate analysis, only lymph node metastasis was associated with persistence/recurrence (coefficient beta 4.0, p = 0.016; 95% CI 1.3-12.9). There were no PTMC related deaths. Conclusions Our series found no mortality and low rate of persistence/recurrence associated with PTMC. Lymph node metastasis was the only feature associated with recurrence in multivariate analysis. The updated ATA 2015 and 8th AJCC/TNM systems classified more PTMCs than previous classifications as low risk of recurrence and mortality, respectively.

摘要

目的 我们旨在描述微小乳头状癌(PTMC)的表现,并确定拉丁美洲队列中与持续存在/复发相关的临床和组织学特征。对象与方法 对接受全甲状腺切除术(无论是否接受放射性碘治疗)且随访至少2年的PTMC患者进行回顾性研究。采用美国甲状腺协会(ATA)2009年和2015年分类评估复发风险,采用美国癌症联合委员会(AJCC)/国际抗癌联盟(TNM)第7版和第8版系统评估死亡风险。随访期间获得的临床数据用于检测结构和生化方面的持续存在/复发情况。结果 我们纳入了209例患者,以女性为主(90%),年龄44.5±12.6岁,183例(88%)接受了放射性碘治疗(90.4±44.2毫居里),中位随访时间为4.4年(范围2.0 - 7.8年)。AJCC/TNM第7版和第8版系统分别将89%和95.2%的患者分类为I期。ATA 2009年和ATA 2015年分别将70.8%和78.5%的患者分类为低风险。15例(7%)患者在随访期间出现持续存在/复发。多因素分析显示,仅淋巴结转移与持续存在/复发相关(系数β为4.0,p = 0.016;95%置信区间1.3 - 12.9)。未发生与PTMC相关的死亡。结论 我们的系列研究发现PTMC相关死亡率低且持续存在/复发率低。多因素分析中,淋巴结转移是与复发相关的唯一特征。更新后的ATA 2015年和AJCC/TNM第8版系统分别将更多的PTMC分类为复发和死亡低风险,较之前的分类有所增加。